Global update on the in vitro activity of tigecycline and comparators against isolates of Acinetobacter baumannii and rates of resistant phenotypes (2016-2018).

Seifert, Harald; Blondeau, Joseph; Lucaßen, Kai; Utt, Eric A

Seifert, Harald; Blondeau, Joseph; Lucaßen, Kai; Utt, Eric A.

Afiliação

Seifert H; Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, Cologne, Germany.
Blondeau J; Clinical Microbiology, Royal University Hospital, Saskatchewan Health Authority and the University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
Lucaßen K; Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, Cologne, Germany.
Utt EA; Pfizer Inc., Hospital Business, External Medical Engagement, Groton Laboratories, Groton, Connecticut, USA. Electronic address: eric.a.utt@pfizer.com.

J Glob Antimicrob Resist ; 31: 82-89, 2022 12.

Article em En | MEDLINE | ID: mdl-35948242

Assuntos

Acinetobacter baumannii; Tigeciclina/farmacologia; Amicacina; Colistina; Meropeném/farmacologia; Levofloxacino; Bactérias Gram-Negativas; Antibacterianos/farmacologia; Fenótipo

Palavras-chave

Acinetobacter baumannii; Antimicrobial resistance; Antimicrobial surveillance; Tigecycline

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Acinetobacter baumannii Tipo de estudo: Guideline Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google